☕ KopiFire
Brew Your Path to FIRE
← Stock Fundamentals

Pharmesis International Ltd.

BFKHealthcarereports in CNY

Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China. The company operates through three segments: Western drugs/TCH Procurement, TCM formulated drugs/IP Rental, and Distribution. It provides prescribed products and over-the-counter drugs. The company offers Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for rheumatoid arthritis and other rheumatic diseases treatment. It also provides Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice and clear heat toxin; Shulinghou for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Fu Yang for the treatment skin pruritus and urticaria; and Xiong Dan Chuan Bei for the treatment of phlegm and cough. Further, the company distributes chemical drugs, biological raw products, TCM products, antibiotics, and antibiotic agents. The company provides western medicine products under the Kinna brand name; and TCM formulated products under the Longlife brand name. Pharmesis International Ltd. was founded in 1996 and is based in Singapore.

Price may be out of date. Price is 20 days old — SGX's feed has not carried a newer one.
Price
S$0.125
Official · 04 Sept 2026
P/E
Yield not calculated
This company reports in CNY but the counter trades in SGD. A per-share figure in CNY cannot be divided by a SGD price, so it is not shown rather than converted at a rate we picked.
Dividend Yield (2026 YTD)
8.00%
Calculated from official data · 04 Sept 2026
P/B
0.38x
Calculated from third-party data · 10 Aug 2026
ROE
-7.34%
Official · 31 Dec 2025
Earnings and balance-sheet figures as reported for FY2025
EPS Growth
-299.01%
Official · 31 Dec 2025
Market Cap
S$0.00B
Calculated from official data · 04 Sept 2026
NAV/Share
S$0.333
Third-party · 10 Aug 2026

Each figure shows where it came from. How we source our numbers →

Dividends

No upcoming ex-date announced yet.

2026 dividends: S$0.01 per security · indicative yield 8.00% at S$0.125 last.

Pays Annual · 2 years of dividends on record, from 2022 onwards.

Full dividend history

Ex-DateAmount / Security
20 Jul 2026S$0.01
20 Aug 2025S$0.01

Dividends by year

YearTotal / SecurityYield*
2026S$0.018.00%
2025S$0.018.00%

*Yield uses the current last price (S$0.125) against each year's total — indicative only.

See the full dividend calendar →

Earnings

No earnings data yet for this counter.

Announcements & news

Fundamentals auto-populated from Yahoo Finance; not hand-verified.

Price synced from SGX. Other figures carry their own source and date above. How we source our numbers